Abstract

BACKGROUND: Apalutamide, a competitive inhibitor of the androgen receptor, is under development for the treatment of prostate cancer. We evaluated the efficacy of apalutamide in men with nonmetastatic castration-resistant prostate cancer who were at high risk for the development of metastasis.

METHODS: We conducted a double-blind, placebo-controlled, phase 3 trial involving men with nonmetastatic castration-resistant prostate cancer and a prostate-specific antigen doubling time of 10 months or less. Patients were randomly assigned, in a 2:1 ratio, to receive apalutamide (240 mg per day) or placebo. All the patients continued to receive androgen-deprivation therapy. The primary end point was metastasis-free survival, which was defined as the time from randomization to the first detection of distant metastasis on imaging or death.

RESULTS: A total of 1207 men underwent randomization (806 to the apalutamide group and 401 to the placebo group). In the planned primary analysis, which was performed after 378 events had occurred, median metastasis-free survival was 40.5 months in the apalutamide group as compared with 16.2 months in the placebo group (hazard ratio for metastasis or death, 0.28; 95% confidence interval [CI], 0.23 to 0.35; P<0.001). Time to symptomatic progression was significantly longer with apalutamide than with placebo (hazard ratio, 0.45; 95% CI, 0.32 to 0.63; P<0.001). The rate of adverse events leading to discontinuation of the trial regimen was 10.6% in the apalutamide group and 7.0% in the placebo group. The following adverse events occurred at a higher rate with apalutamide than with placebo: rash (23.8% vs. 5.5%), hypothyroidism (8.1% vs. 2.0%), and fracture (11.7% vs. 6.5%).

CONCLUSIONS: Among men with nonmetastatic castration-resistant prostate cancer, metastasis-free survival and time to symptomatic progression were significantly longer with apalutamide than with placebo. (Funded by Janssen Research and Development; SPARTAN ClinicalTrials.gov number, NCT01946204 .).

Original languageEnglish
JournalNew England Journal of Medicine
Volume378
Issue number15
Pages (from-to)1408-1418
ISSN0028-4793
DOIs
Publication statusPublished - 12. Apr 2018

Keywords

  • Adenocarcinoma/drug therapy
  • Aged
  • Aged, 80 and over
  • Androgen Antagonists/adverse effects
  • Disease Progression
  • Disease-Free Survival
  • Double-Blind Method
  • Exanthema/chemically induced
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Metastasis/prevention & control
  • Proportional Hazards Models
  • Prostate-Specific Antigen
  • Prostatic Neoplasms, Castration-Resistant/drug therapy
  • Thiohydantoins/adverse effects

Fingerprint

Dive into the research topics of 'Apalutamide treatment and metastasis-free survival in prostate cancer'. Together they form a unique fingerprint.

Cite this